Skip to content

Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research

Mobile Terminal Based Management and Platelet Reactivity Modified Drug Regulation of Stroke Secondary Prevention

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02618265
Enrollment
400
Registered
2015-12-01
Start date
2016-01-31
Completion date
2018-12-31
Last updated
2015-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, secondary prevention, platelet response polymorphism, mobile terminal

Brief summary

The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

Detailed description

With high incidence, mortality, morbidity and recurrence rate,stroke has significant impact on national development strategies planning. Improving secondary prevention will strongly promote stroke management in the rapid developing phase of Chinese economy and expansion of health situation. At present lack of high-quality medical resources, low medical permeability cannot remedy extensive prevention failure of stroke. Mobile healthcare is easier to conduct and still in the early stage of explosive growth. This research group has established an open management platform of stroke prevention. And collaborate with Peking University Institute of Information Technology to develop a smart phone application which can be personalized medication reminder, record medication compliance, home blood pressure and blood glucose test results, also can provide doctor-patient communication platform and symptoms alarm. The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform. Whole blood-impedance based platelet aggregation(WBA) method and VerifyNow detected by aspirin or clopidogrel responsiveness will provide individualized anti-platelet drug selection. Control group will be selected from the National Stroke data registration database platform and open platform for stroke prevention. Follow-up period is 2 years. Endpoint event is defined as stroke death or relapse. Primary measure outcomes are change of the stroke recurrence rate and mortality after secondary prevention.

Interventions

PROCEDUREMobile terminal

multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment

aspirin or clopidogrel monotherapy or double treatment for

PROCEDUREwebsite platform management

second prevention based on website platform management

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* stroke

Exclusion criteria

* refusion in research

Design outcomes

Primary

MeasureTime frameDescription
change of the stroke recurrence rate2 years stroke recurrence rateAfter secondary prevention

Secondary

MeasureTime frameDescription
change of the stroke mortality2 years stroke mortalityAfter secondary prevention

Countries

China

Contacts

Primary ContactDongsheng Fan
dsfan@sina.com+861082265032

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026